Other safety alerts
|
| |
| Australia: Counterfeit Botox vials detected |
| |
The Therapeutic Goods Administration (TGA) announces that consumers and health professionals should be aware that two unrelated cases of counterfeit injectable botulinum toxin products have been stopped at the Australian border. The counterfeit products were packaged to appear as genuine, branded, Botox products, manufactured by Allergan, an AbbVie company. These injectable products may pose a serious risk to your health and should not be used.
The counterfeit products were labelled as Botox, containing onabotulinumtoxinA and botulinum toxin type A. However, packaging inconsistencies were identified, including typographic errors like incorrect spacing, bolding and spelling mistakes. Additionally, the batch numbers C7211C4 and HA 33946 have been confirmed by AbbVie as not genuine.
Counterfeit products have not been assessed by the TGA for quality, safety or efficacy as required under Australian legislation. Consumers should be warned that manufacturers of counterfeit goods are producing products that, to the untrained eye, may appear legitimate, highlighting the need to purchase your medicines from legitimate sources. The TGA advises consumers to exercise extreme caution when purchasing medicines from unknown overseas websites.
Please refer to the following website in TGA for details:
http://www.tga.gov.au/news/safety-alerts/counterfeit-botox-vials-detected
In Hong Kong, Botox For Inj 100 Units (HK-41906) is a pharmaceutical product registered by Allergan Hong Kong Limited. The product is a prescription-only medicine. The pack of the counterfeit Botox product mentioned in the above TGA’s announcement is different from the registered pack of the product in Hong Kong.
Ends/Friday, Jul 11, 2025
Issued at HKT 15:45
|
| |
|
